CADD is a cutting-edge computational method used to locate and develop a promising lead in the drug discovery process. Molecular modelling, molecular design, computational chemistry, and rational drug design are all components of computer-aided drug design. To maximise discovered leads, CADD is being employed. Both in academic communities and the pharmaceutical companies, CADD approaches are becoming more well-liked and respected. Time is saved, and the CADD technique is quick and economical. The four steps of the CADD method are as follows: (1) use a virtual screening (VS) protocol to screen a small molecule library against the target to find hits or leads, (2) examine the specificity of the selected hits from VS using molecular docking in the active site of other recognized targets, and (3) predict ADMET properties of the selected hit using in silico techniques and the most promising hits are referred to as leads and step four assists in optimizing the leads by creating better compounds for synthesis and testing. Structure-based and ligand-based drug design are the two categories into which CADD approaches are divided depending on the availability of the target protein's 3D structure (SBDD and LBDD). The pharmacological target's 3D structure is necessary for SBDD. The target structure can be obtained in one of two ways: (1) by downloading it from the Protein Data Bank (PDB) if the protein structure has been solved by crystallography and (2) employ molecular modeling (a bioinformatics technique) to forecast the structure if the protein structure cannot be determined.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia